Catherine Bollard, MBChB, M.D.
Professor, Center for Cell and Gene Therapy, Departments of Pediatrics, Medicine, and Pathology & Immunology
Otago Medical School, Dunedin New Zealand
FRACP, The Royal Australasian College of Physicians, Auckland, New Zealand
RCPA, The Royal College of Pathologists of Australasia, Auckland, New Zealand
Dr. Bollard's research interests include the augmentation of anti-tumorimmunity against leukemic cells following stem cell transplants usingcytotoxic T cells (CTL) directed against minor histocompatibility antigens. She is also evaluating the efficacy of Epstein Barr Virus (EBV)-specific CTL in patients with relapsed EBV positive Hodgkin's Disease including the use of EBV-CTL as adjuvant therapy post autologous stem cell transplant. Dr Bollard is also developing gene therapy strategies to counteract tumor immune evasion mechanisms to enhance the efficacy of adoptive immunotherapy protocols.
Specifically, in collaboration with Drs Heslop and Rooney, she demonstrated a method of genetically modifying EBV-specific T-cells to improve their potential as cell therapy for Hodgkin Disease. The use of a dominant negative TGFb Receptor mutant to transduce CTL is likely to improve cell therapy for patients with not only Hodgkin's Disease, but also other lymphomas and carcinomas which use TGFb secretion as a means to evade the immune response.
- Straathof KC, Leen A, Brenner MK, Heslop HE, Rooney CM, Bollard CM. “Epitope mapping in CTL derived from patients with type II latency EBV+ tumors” J Immunol. 2005 Sep 15;175(6):4137-47.
- Lacuesta KC, Buza E, Hauser H, Pule M, Brenner MK, Heslop HE, Rooney CM, Bollard CM. “Assessing the Safety of Cytotoxic T Lymphocytes transduced with a dominant negative TGF-Receptor in vivo” JIT 2006 May/June;29(3):250-260
- AM Leen, GD Myers, U Sili, MH Huls, H Weiss, KS Leung, G Carrum, RA Krance, JJ Molldrem, AP Gee, MK Brenner, HE Heslop, CM Rooney, CM Bollard. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised patients. Nat Med. 2006 Nov;12(10):1160-1166
- CM Bollard, S Gottschalk, AM Leen, H Weiss,KC Straathof, G Carrum, M Khalil, M Wu, MH Huls, CCChang, MV Gresik,AP Gee, MK Brenner,CM Rooney, HE Heslop. Complete Responses of Relapsed Lymphoma Following Genetic Modification of Tumor-Antigen Presenting Cells and T lymphocyte transfer.Blood Blood. 2007 Oct 15;110(8):2838-45.
- Leen AM, Christin A, Khalil M, Weiss H, Gee AP, Brenner MK, Heslop HE, Rooney CM, Bollard CM. Identification of hexon-specific CD4 and CD8 T-cell epitopes for vaccine and immunotherapy. J Virol. 2008 Jan;82(1):546-54. Epub 2007 Oct 17.PMID: 17942545 [PubMed - indexed for MEDLINE]
- Leen AM, Christin A, Myers GD, Liu H, Cruz CR, Hanley PJ, Kennedy-Nasser AA, Leung KS, Gee AP, Krance RA, Brenner MK, Heslop HE, Rooney CM, Bollard CM. Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation. Blood. 2009 Nov 5;114(19):4283-92. Epub 2009 Aug 21.PMID: 19700662 [PubMed - in process]
- Hanley PJ, Cruz CR, Savoldo B, Leen AM, Stanojevic M, Khalil M, Decker W, Molldrem JJ, Liu H, Gee AP, Rooney CM, Heslop HE, Dotti G, Brenner MK, Shpall EJ, Bollard CM. Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes Blood. 2009 Aug 27;114(9):1958-67. Epub 2009 May 14.PMID: 19443656 [PubMed - indexed for MEDLINE]
Tx Childs Feigin Ctr, #75007